Mr. Rashid Bux reports

BIOMARK: 2025 ACHIEVEMENTS & 2026 VISION

Biomark Diagnostics Inc. has issued a year-end letter to its shareholders and team from its chief executive officer and founder, Rashid Ahmed Bux.

Dear Biomark shareholders and team,

As we reflect on 2025, we celebrate a transformative year that positions Biomark as the leader in early cancer detection and precision diagnostics. What we have accomplished together represents not just scientific breakthroughs. It represents the resilience, dedication and unwavering commitment of our team to a mission that saves lives.

Key achievements in 2025

Team and capacity:

• Expanded technical team: strengthened scientific and operational capabilities with strategic talent additions;
• Doubled throughput capacity: scaled laboratory infrastructure to meet clinical and commercial demands;
• Artificial intelligence/machine learning investment: enhanced data analytic capabilities to improve diagnostic accuracy.

Regulatory and clinical validation:

• ISO 15189 certification documents submitted in December, 2025: for international laboratory standards compliance, and, once secured, it will help position us for CLIA and CAP accreditation as we enter the U.S. market;
• HANSE (10,000) trial selection: chosen as exclusive partner for the largest prospective lung cancer study since the Nelson trial -- unprecedented data access and platform validation;
• 7,000-plus-patient study completed: Canada's largest lung cancer diagnostic study, generating robust real-world evidence and biomarker validation.

Scientific leadership and recognition:

• Six-plus peer-reviewed publications: featured in high-impact journals as thought leaders in metabolomics and artificial-intelligence-based oncology diagnostics;
• CQDM innovation prize: industry recognition for our innovative approach to cancer detection (partnership with IUCPQ);
• Featured in Canadian Securities Exchange technology issue June, 2025: recognized as a leading Canadian biotech company advancing precision medicine.

Strategic financing and partnerships:

• $4.5-million capital raised: secured substantial financing in a challenging small-capitalization market -- powerful testament to investor confidence;
• NRC Horizon Europe financing: European expansion and collaborative research support secured;
• Secured City of Quebec funding;
• Manitoba Lung Association grant: pilot first nations lung cancer detection program -- advancing health equity and community access;
• Quebec RNA hub letter of intent submitted: positioned for AReNA program funding supporting miRNA-LNP platform development for RNA therapeutics.

What this means for our stakeholders

For Our team

You are part of an internationally recognized leader in early cancer detection. Your work directly impacts patient outcomes. Our team expansion reflects confidence in our mission. We hire the best because our science demands excellence. You are changing cancer detection.

For our shareholders:

• Validated platform: HANSE trial selection and 7,000-plus-patient data provide strong clinical evidence for commercialization.
• Derisked regulatory path: ISO 15189 certification unlocks CLIA accreditation and U.S. market entry (16-million-plus at-risk population requiring annual lung cancer screening).
• Diversified revenue model: Government, foundations and industry partnerships validate multiple market pathways.
• International expansion: Horizon Europe financing opens European opportunities.
• Environmental, social and governance differentiation: First nations health equity program positions us attractively for impact-focused investors.

2026 catalysts

Regulatory and market access:

• ISO 15189 accreditation approval will support CLIA/CAP application for the U.S. market commencement;
• U.S. reimbursement strategy development: collaborate with screening centres and payers as clinical data expands.

Intellectual property competitive positioning:

• Broaden IP estate: strengthen patent protection for biomarker discovery and diagnostic innovations.

Clinical data and publications:

• HANSE lung cancer trial data generation: first longitudinal validation from 10,000-patient study; this is the second-largest longitudinal trial since the Nelson trial was held in 2013;
• 7,000-patient study publication: high-impact manuscripts accelerating commercial partnerships.

Commercial expansion:

• Industry licensing negotiations: major pharma, lab and diagnostic partnerships leveraging publication and trial data;
• Laboratory service launch: ISO 15189-certified clinical diagnostic services; CRO service offerings;
• Expand distribution channels: medical and clinic chains.

Business scaling:

• Leadership roles: patient engagement and revenue-generating officers (to optimize consumer experience and financial performance) and a medical director (to ensure clinical integrity);
• Technical and operational experts: data specialists, scientists and lab technicians (to enhance research and development and laboratory efficiency);
• Business development: business development managers (to secure partnerships and expand market reach);
• Appointment of a new member of the board of directors -- supports U.S. market entry.

Outreach:

• International collaboration: secure licensing agreements in strategic geographic markets.

Revenue and coverage:

• Revenue generation: LDT (lab-developed test) sales, CRO services and diagnostic tests;
• Strategic financing: secure follow-on financing at an elevated valuation based on clinical validation and revenue traction;
• Analyst coverage: position for institutional investor engagement and market visibility.

Our culture: a message of resilience

To every member of the Biomark family -- from lab scientists to business development, clinical operations, regulatory affairs and leadership -- thank you.

This year tested us. We navigated regulatory complexity. We managed ambitious timelines. We scaled operations while maintaining scientific rigour. We faced skepticism and answered with data. We never backed down.

That spirit -- that refusal to accept no as final, that commitment to excellence even when the path is uncertain -- that is Biomark's culture. That is what makes us different.

We are defined by:

• Resilience: Challenges become opportunities. Setbacks become insights.
• Dedication: Our team believes in the mission, not titles or accolades.
• Excellence: We accept nothing less than the highest standards in science, operations and patient care.
• Never backing down: When the path is unclear, we forge forward. When obstacles appear, we find solutions.

The investors who backed us, the patients who entrusted us with their samples, the health care collaborators who partnered with us -- they did so because they saw a team that delivers.

In 2026, we will expand that impact. We build upon the achievements of 2025. Together, we will establish Biomark as the global standard in early cancer detection, transform patient outcomes and do it with the same unwavering commitment that got us here.

Our vision: 2026 and beyond:

• By the end of 2026: regulatory accreditation complete, clinical partnerships announced and revenue-generating services launched;
• By 2027: market leadership established; expansion into metabolic disease diagnostics;
• By 2028: international presence across North America and Europe; transformed cancer detection landscape.

We have the science. We have the team. We have the partnerships. We have the resolve.

The best of Biomark is not behind us. It is ahead of us.

Thank you for your trust, your hard work and your belief in what we're building. Let us finish 2025 strong and make 2026 unforgettable.

With deep gratitude and unwavering commitment,

The Biomark leadership team

About Biomark Diagnostics Inc.

Biomark is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.